Kiniksa Pharmaceuticals(KNSA)
MA - LexingtonPharmaceutical
Focus: Kiniksa is a publicly traded specialty pharma company focused on biologics and monoclonal antibodies for inflammatory diseases, headquartered in Lexington, MA. The company operates with $270M in FY2025 revenue, primarily from its flagship IL-1 inhibitor ARCALYST.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
20
Should You Work at Kiniksa Pharmaceuticals?
AI assessmentKiniksa offers clinical/commercial growth opportunities in a stable, innovation-focused setting, but revenue concentration and patent cliff exposure require clarity on pipeline success before committing long-term.
Why Work Here
- Strong cash position ($184M) and profitable operations (FY2025: $14M net income) provide stability for mid-sized biopharma roles
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$270M
Key Products
$25M Part DDeclining
LOE Approaching
Sole revenue driver generating 100% of company sales; IL-1α/β cytokine trap with strong binding affinity (0.5 pM for IL-1β) but facing generic/biosimilar competition.
Help build intelligence for Kiniksa Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.